University of Washington Professor Jeffrey Chamberlain, a leading researcher in muscular dystrophy, discussed advancements in gene therapy for Duchenne muscular dystrophy (DMD) at a conference in July 2025. Chamberlain, the McCaw Endowed Chair in Muscular Dystrophy at the University of Washington School of Medicine, detailed ongoing research into next-generation DMD treatments.
Chamberlain directs the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Seattle, focusing on understanding the molecular basis of muscular dystrophies and developing gene and cell therapies. His laboratory, comprised of approximately 15 scientists, is working to translate research into clinical trials. Collaborations extend to Children’s Hospital, Fred Hutchinson Cancer Research Center, University of Rochester, and Harborview Medical Center.
Research efforts center on Duchenne muscular dystrophy and LGMD2I, targeting the dystrophin gene and the FKRP gene. Chamberlain’s lab is developing vectors to deliver dystrophin or other genes to muscle tissue for gene therapy, with ongoing safety testing and evaluation of their ability to halt or reverse the disease’s progression. A 2017 publication co-authored by Chamberlain and Joel R. Chamberlain in Molecular Therapy highlighted the 30-year history of gene therapy development for DMD, noting the challenges posed by the gene’s size and the volume of muscle tissue involved.
The research builds on the landmark discovery of the defective DMD gene, which was cloned without prior knowledge of the protein product. Chamberlain’s work explores the use of vectors, including adeno-associated viruses (AAV), to deliver genetic material. The 2017 publication detailed comparative domain structures of full-length dystrophin, mini-dystrophin, and micro-dystrophin proteins, illustrating efforts to create functional dystrophin proteins despite genomic deletions.
In October 2025, Chamberlain co-authored an article in ScienceDirect with Józef Dulak, focusing on genetic strategies for the therapy of Duchenne muscular dystrophy. The article details the severe, X-linked nature of the disease and the ongoing efforts to develop effective treatments.
